← Leaderboards
Andrea Anne Stierle
Montana Technological University
$630,514
Attributed
$630,514
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $215.9K · FY2009–11$250K$187.5K$125K$62.5K$0
'09
'10
'11
Funding mix
By agency
NIH$630,514 · 1
By mechanism
R01$630,514 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAmericanAnticancer ActivityAntineoplastic AgentsAreaBaseBiological FactorsBiomedical ResearchCancer Cell LineCancer TypeCaspase-1Cause Of DeathCell LineCytotoxic AgentCytotoxicityDevelopmental Therapeutics ProgramDiagnosisDrug DiscoveryEnvironmentEnzyme InhibitionEnzyme Inhibitor DrugsEnzyme InhibitorsEnzymesAcids
Grant awards (3)
Signal Transduction Enzyme Inhibitors from Extremophilic Microbes as Anticancer A$209,710
R01 · FY2011 · CA · contact PI
Signal Transduction Enzyme Inhibitors from Extremophilic Microbes as Anticancer A$215,936
R01 · FY2010 · CA · contact PI
Signal Transduction Enzyme Inhibitors from Extremophilic Microbes as Anticancer A$204,868
R01 · FY2009 · CA · contact PI